South & Central America Balloon Aortic Valvuloplasty Market

The South & Central America balloon aortic valvuloplasty market was valued at US$ 12.02 million in 2023 and is expected to reach US$ 17.24 million by 2031; it is estimated to register a CAGR of 4.6% from 2023 to 2031.

Rising Prevalence of Aortic Valve Stenosis Fuels South & Central America Balloon Aortic Valvuloplasty Market

Heart valve disease (HVD) is a cardiac defect increasingly linked to functional decline, especially in aging individuals. HVD can cause stenosis, regurgitation, or a combination of the two in any of the four valves. As the incidence of HVD prominently increases with aging, it is estimated to affect millions globally in the upcoming years. The narrowing of the aorta can make it difficult for blood to flow from the heart to various parts of the body, resulting in a condition called aortic stenosis. As the heart is under considerable pressure while pumping blood through the constricted aorta, it leads to symptoms such as shortness of breath, chest pain, and fatigue. The high-risk patient populations are inoperable and cannot undergo surgical aortic valve replacement procedures. Aortic stenosis prevalence exponential increases with age, displaying 0.2% in people aged 50–59 years, 1.3% in the 60–69 year group, 3.9% in the 70–79 year group, and 9.8% in people aged 80–89 years. The high prevalence of aortic valve stenosis is surging the demand for balloon aortic valvuloplasty (BAV) devices. BAV is less invasive than conventional open-heart surgery, making it a more attractive option for patients. Transcatheter aortic valve implantation (TAVI), also called transcatheter aortic valve replacement (TAVR), has become a well-established therapeutic option for severe aortic stenosis. BAV is a crucial procedural step during TAVI to predilate the valve in order to enhance transcatheter delivery. TAVI has emerged as a ground‐breaking, minimally invasive alternative to traditional open‐heart surgery, primarily designed for aged patients initially considered unsuitable for surgical intervention due to severe aortic stenosis. Thus, the growing prevalence of aortic valve stenosis worldwide drives the balloon aortic valvuloplasty market growth.

South & Central America Balloon Aortic Valvuloplasty Market Overview

The South & Central America balloon aortic valvuloplasty market is segmented into Brazil, Argentina, and the Rest of South & Central America. In South & Central America, Brazil is among the 10 countries with the largest population of older people who are the main users of the public health system. The market in the region is expected to grow due to the surge in the aging population who are susceptible to heart diseases, as well as initiatives undertaken by various government organizations to create awareness about valve replacement surgeries.

According to the Pan American Health Organization, Brazil has more than 30 million people aged 60 years and above, representing 13% of the country’s population. By 2031, this age group will reach nearly 50 million, which will be 24% of the total Brazilian population. As per the Brazil Statistical Institute, the country’s population aged 65 and above is expected to hold a share of 36% of the total population by 2050. According to Instituto Nacional de Estadística y Censos, in 2020, 15.7% (7.1 million people) of the population of Argentina was over 60 years. It is estimated to rise to 22% by 2050, i.e., ~12.5 million people, and the figure will reach 34% by 2100, accounting for ~20 million individuals.

According to the Department of Economic and Social Affairs, ~11.5% of the population in Chile was reported to be over 65 years of age in 2019, which is projected to reach 21% by 2041. In addition, Peru has a huge portion of people aged 60 and above. As per El Instituto Nacional de Estadística e Informática (INEI) 2020 data, older adults make up more than 4 million (47.8% men and 52.2% women), representing 12.7% of the population in the country; this is more than twice as much as in 1950, where this population group represented 6%. Demographic data shows that the number of inhabitants aged 65 and above has grown progressively over the last decade and reached 2.99 million in 2021. Similarly, as per AARP International data, in Costa Rica, people aged 60 and above represented 9% of the total population in 2021. This proportion is expected to double by 2050, as older adults will account for ∼20% of the population in the country. The prevalence of heart diseases, including heart valve diseases, increases with age, owing to which there is a significant demand for TAVI procedures.

In the past, due to economic crises, Brazil faced several challenges in terms of healthcare expenditure, infrastructure, and healthcare services. However, the implant & device industry across the country witnessed tremendous growth owing to the geographical expansion of market players and the development of innovative and advanced products. The country has positive influence from the neighboring countries, which has amplified the use of heart devices.

Furthermore, in January 2022, MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) received marketing approval for its TAVI solution, the new-generation VitaFlow Liberty Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty) by the Argentine National Administration of Drugs, Foods, and Medical Devices. Thus, the aforementioned factors increase the demand for aortic replacement devices, thereby influencing the market growth in the region.

South & Central America Balloon Aortic Valvuloplasty Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Balloon Aortic Valvuloplasty Strategic Insights

Strategic insights for the South & Central America Balloon Aortic Valvuloplasty provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Balloon Aortic Valvuloplasty Report Scope

South & Central America Balloon Aortic Valvuloplasty Regional Insights

The geographic scope of the South & Central America Balloon Aortic Valvuloplasty refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Balloon Aortic Valvuloplasty Market Segmentation

The South & Central America balloon aortic valvuloplasty market is categorized into product type and country.

Based on product type, the South & Central America balloon aortic valvuloplasty market is segmented into non compliant balloons and semi compliant balloons. The non compliant balloons segment held the largest market share in 2023.

By country, the South & Central America balloon aortic valvuloplasty market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America balloon aortic valvuloplasty market share in 2023.

B Braun SE; TT Medical, Inc.; Balton; Becton Dickinson and Co; Edwards Lifesciences Corp; Balt; and Venus MedTech HangZhou Inc are some of the leading companies operating in the South & Central America balloon aortic valvuloplmarket.